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Summary: Administration of L-caniitine or betamethasone to pregnant rats failed to increase either the total
phospholipid or dipalmitoylphosphatidylcholine (DPPC) contents in foetal rat lungs on the 20th day of
j gestation, eompared to cpntrols. The combined administration of betamethasone (0.3 mg/kg) and L-carnitine
; (80 mg/kg) resulted in a pronounced increase of dipalmitoylphosphatidylcholine (7.8 ±2.5 mg/g dry weight)
j coinpared with the control group (5.4 ± 1.8 mg/g dry weight), and compared with the groups receiving
betamethasone (5.9 ±1.9 mg/g dry weight) or L-carnitine (5.6 + 1.5 mg/g dry weight) alone. The proportion
of dipalmitoylphosphatidylcholine in the phosphatidylcholine species increased from 20.9 ±2.1% in the
foetal lungs of the control group to 22.6 ± 5.0% in the L-carnitine group, to 24.3 + 3.3% (p < 0.01) in the
betämethasone-i-carnitine (20 mg/kg) group, to 25.2 ± 3.5% (p < 0.01) in the betamethasone group, to
27.1 + 2.6% (p < 0.01) in the betamethasone-L-carnitine (40 mg/kg) group, and to 28.4 ± 3.7% (p < 0.01)
in the betamethasone-L^carnitine (80 mg/kg) group, while the palmitic acid portion in the phosphatidylcholine
fatty acids was nearly unchanged. A pronounced increase of palmitoyl-myristoyl phosphatidylcholine (PC-
30), the second disaturated phosphatidylcholine species present in lungs in significant amounts beside
dipalmitoylphosphatidylcholine, was noted only in betamethasone treated animals. Furthermore, after beta-
methasone and betamethasone^carnitine treatment, a significant diminution (p < 0.01) of the proportion
of palmitoyl-palmitoleyl phosphatidylcholine (16 : 0/16 : l-PC) in the phosphatidylcholine species was demon-
strated. After L-carnitine and betamethasone-L-carnitine treatment a significant increase (p < 0.01) of the
Proportion of palmitoleyl-palmitoyl phosphatidylcholine (16 :1/16 : 0-PC) in the phosphatidylcholine species
was found. Administration of L-carnitine to pregnant rats (either alone or in combination with betamethasone)
resulted in a significant elevation (p < 0.01) of the carnitine levels in the foetal lungs to approximately twice
those of the controls.
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The results suggest that a betamethasone-L-carnitine combination has both additive effects and effects
specific for the combination, neither of which are found when carnitine or betamethasone is administered
alone.
Studien über die Wirkung von Betamethason, L-Carnitin und Betamethason-L-Carnitin-Kombinationen auf
den Dipalmitoylphosphatidylcholingehalt und die Zusammensetzung der Phosphatidylcholfy-Spezies von fetalen
Rattenlungen
Zusammenfassung: Die Verabreichung von L-Carnitin oder von Betamethason an gravide Wistarratten
führte zu keinem Anstieg des Gesamtphospholipid- und Dipalmitoylphosphatidylcholiiigehalts in den fetalen
Rattenlungen im Vergleich zur Kontrollgruppe. Andererseits wurde nach Applikation einer Betamethason
(0,3 mg/kg)-L-Carnitin (80 mg/kg) Kombination ein deutlicher Anstieg des Dipalmitoylphosphatidylcholinge^
halts (7,8 + 2,5 mg/g Trockengewicht) im Vergleich zur Betamethason- (5,9 ± l,9 mg/g Trockengewicht),
L-Carnitin- (5,6 ± l,5 mg/g Trockengewicht) und der Kontrollgruppe (5,4 ± l,8 mg/g Trockengewicht)
gefunden. Der Prozentanteil des Dipalmitoylphosphatidylcholins an den Phosphatidylcholinspezies erhöhte
sich von 20,9 + 2,1% (Kontrollgruppe) auf 22,6 ± 5,0% nach Verabreichung von L-Carnitiri, auf 25,2 ±
3,5% (p < 0,01) nach Betamethasonbehandlung und nach Gaben von Betamethason-L-Carnitin Kombinatio--
nen bei 20 mg/kg L-Carnitin auf 24,3 ± 3,3% (p < 0,01), bei 40 mg/kg L-Cärnitin auf 27,1 ± 2,6%
(p < 0,01) und auf 28,4 ± 3,7% (p < 0,001) mit 80 mg L-Carnitin. Trotz des signifikanten Anstiegs des
Dipalmitoylphosphatidylcholins zeigte der prozentuale Anteil der Palmitinsäure an den im Phosphatidylcholin
veresterten Fettsäuren nur geringe Veränderungen. Nur in der Betamethasongruppe findet sich ein deutlicher
Anstieg von Palmitoyl-myristoyl-phosphatidylcholin (PC 30), neben Dipalmitoylphosphatidylcholin die zweite
mengenmäßig wichtige gesättigte Phosphatidylcholinspezies. Außerdem kam es nach Betamethasonbehand-
lung sowie nach Applikation von Betamethason-L-Carnitin Kombinationen zu einer signifikanten (p < 0*01)
Verminderung des Anteils von Palmitoyl-palmitoleyl-phosphatidylcholin (16 : 0/16 :1-PC) am Phosphatidyl·
cholin. Nach L-Carnitin-Behandlung und nach maternaler Applikation einer Betamethason-L-Carnitin-
Kombination wurde ein signifikanter Anstieg (p < 0,01) des prozentualen Anteils von Palinitoleyl-palmitoyk
phosphatidylcholin (16:1/16: 0-PC) am Phosphatidylcholin gefunden. Applikation von L-Carnitin sowohl
allein, als auch in Kombination mit Betamethason an gravide Ratten führte zu einem signifikanten Anstieg
(p < 0,01) des Gesamt-Carnitingehalts in den fetalen Lungen. Diese Gehalte waren annähernd doppelt so
hoch wie jene der unbehandelten oder mit Betamethason behandelten Tiere.
Die Ergebnisse der vorliegenden Studie weisen auf zwei unterschiedliche Wirkungen einer Betamethason-L-
Carnitin-Kombinationsbehandlung hin: erstens solche, die einer additiven oder subtraktiven Wirkung der
beiden Einzelkomponenten entsprechen, und zweitens Effekte, die offensichtlich spezifisch für eine Betametha-
son-L-Carnitin-Kombination sind.
Introduction cussed with regard to efficacy and possible side
Surfactant deficiency is one of the most important
factors underlying the development of the respiratory We have previously shown (4) that antepartum ad-
distresssyndrome(RDS)intheimmaturelungofthe ministratioh of L-carnitine or betamethasone en-
newborn. Dipalmitoylphosphatidylcholine (DPPC) hances the dipalmitöylphosphatidylcholine content in
constitutes the major fraction of the surfactant com- the lunSs of foetuses delivered on the 21st gestational
plex and is mainly responsible for the surface active day- The results suggested that L-carnitine .and beta-
properties (1—3). methasone affect the dipalmitöylphosphatidylcholine
A ! .·
 f r . , \ * · level in foetal lung via two dissimilär mechanisins.Acceleration of foetal lung development with exogen- 6
ous glucocorticoids has been demonstrated in ä large In the present study we attempted to examine the
number of animal models, with various species, using effects of maternal treatment with betamethasörie-L^
physiological, morphological, and biochemical para- carnitine combinations in comparison to the adminis-
meters. Such experimental findings have supported tration of L-carnitine and betamethasone alone. To
the clinical üse of glucocorticoids in cases of imminent evalüate the effects of the different treatments, we
premature delivery or when progressive intrauterine detennined both the dipalmitöylphosphatidylcholine
damage makes premature delivery necessary. In the content and the proportion of dipalmitoylphosphati-
recent past corticosteroid prophylaxis of foetal respir- dylcholine in the total phosphatidylcholine of foetal
atory distress syndrome has been increasingly die- rat lungs. * *
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Materials and Methods
Seventy-five female Wistar rats of stock Ch bb-Thom with an
average weight of 300 g and an expected gestation period of
23 days were randomized and divided into six groups. The
gestational age was known within 24 hours. The rats were
treated intraperitoneally from the 16th to the 19th day of
gestation by the following schedule:
Group Beta- L-Carni-
methasone tine
(mg/kg) (mg/kg)
Solute
Controls
Betamethasone 0.3
L-Carnitine
Bethamethasone + 0.3
L-Carnitine
0.3
0.3
20
20
40
80
l ml/day
physiological
saline
l ml/day
distilled
water
l ml/day
distilled
water
l ml/day
distilled
water
l ml/day
distilled
water
l ml/day
distilled
water
Higher carnitine doses (60, 80,100 nag/kg) showed effects which
were not significantly different from those with 20 mg/kg body
weight.
Preparation of lung tissue
Immediately after delivery the foetal trachea was clamped be-
fore spontaneous Inspiration could occur. The foetuses were
thoracotomized by means of parasternal incision. The foetal
lungs were then grouped according to litter in order to preclude
station-related differences. The foetal lungs were homogenized,
extracted, and washed using the method of Folch et al. (5).
Phospholipid analysis
Total phospholipids were assayed by a mpdified version of
Bartletfs method (6). The main phpspholipid classes were sep-
arated äs bands by tidiiflayer chromatography using the solvent
System chloroform/methanol/lO g/l potassium Chloride solution
(volümes, 43 + 4 7 + 4 ) (4). 1,2 Dipalmitoyl-sn-glycero-3-
phosphpchpline (PPPC) and the glycero-3-phosphocholine spe-
cies composition were assayed äs the corresponding diacylgly-
cerpl trimethylsiiylether derivatives by gas-liquid chromatogra-
phy with glass capillary columns (7, 8). Phosphatidylcholine
fatty acids were determined äs methyl ester derivatives by gas-
liquid chromatography with glass capillary columns.
Carnitine assay
The tissue was flash-frozen immediately after removal. The
perchloric acid extracts were üsed for assaying free and short-
chain acylcarnitine. The carnitine esters were saponified and
assayed äs free carnitine by radioenzymatic means (9), with
two modiflcations: HEPES instead of TRIS buffer (10), and
N-ethylmaleimide instead of tetrathionate (11).
Chemicals
"L-Carnitin-Leopold" was obtained from Leopold Ltd. (Graz,
Austria). Chloroform, methanol, pyridine, hexamethyldisila-
zane, thin-layer chromatography plates (silica gel 60), and HE-
PES were obtained from E. Merck (Darmstadt, F. R. G.). Ba-
cillus ce/ms-derived phospholipase C and carnitine acetyl-
transferase were obtained from Boehringer-Mannheim
(R R. G.). Labeled acetylcoenzyme A was obtained from New
England Nuclear (Boston, Mass.). N-ethylmaleimide and di-
myristoyl-sn-glycero-3-phosphocholine were supplied by Sigma
Chemical Company (St. Louis, MO.).
Statistical analysis
Statistical cornparisons between the control group and the
treated groups were made using analysis of variance followed
by Dünnet*s t-test for multiple comparison.
Results
Total phospholipid content
Only small differences in the total phospholipid con-
tent in foetal rat* lungs were found in the different
treatment groups (data not shown).
Dipalmitoylphosphatidylcholine
Both betamethaspne and L-carnitine treatments in-
duced only a moderate increase in the dipalmitoyl-
phosphatidylcholine content compared with the con-
trol group. However, the combined administration of
betamethasone and Z/-carnitine resulted in a marked
increase in the dipalmitöylphosphatidylcholine con-
tent (tab. 1). The proportion of dipalmitöylphospha-
tidylcholine in the phosphatidylcholine species exhi-
bited a significant rise (p < 0.01) in the betametha-
sone group, and the betamethasone-L-carnitine com-
bination groups. Only a moderate response to L-
carnitine administration was noted (tab. 1).
Phosphatidylcholines contaiiiing palmitic
and palmitoleic acid
(PC-32 monoenic species)
We have previously shown that the PC-32 monoenic
species can be characterized äs 16 : 0/16 : l-PC and
äs 16:1/16:0-PC (4). A relatively high portion of
16 :1/16 : 0-PC in the phosphatidylcholine species is
probably characteristic for foetal lungs (4) and amni-
otic fluid (12). The portions of 16 : 0/16 : l-PC and
of 16 :1/16 : 0-PC in the phosphatidylcholine species
of the foetal lungs are shown in table 1.
16:0/16: 1-PC is significantly lower (p < 0.01) in
the betamethasone-treated group than in the control
group. A moderate diminution was found after L-
carnitine administration. Interestingly, in the beta-
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Tab. 1. PC-32 species in foetal rat lungs*)
Treatment Dipalmitoylphos-
phatidylcholine
Percentage of PC-32 species in total phosphat-
idylcholines
(16:0/16: 0-PC) 16:0/16:0-PC
(mg/g dry weight)
16:0/16:1-PC 16:1/16:0-PC
NaCl (Controls)
Betamethasone (0.3 mg/kg)
Carnitine (20 mg/kg)
Betamethasone + Carnitine (20 mg/kg)
Betamethasone + Carnitine (40 mg/kg)
Betamethasone + Carnitine (80 mg/kg)
16
14
6
12
10
12
5.4 ± 1.8
5.9 ± 1.9
5.6 ± 1.5
6.6 + 1.6
6.5 ± 1.7
7.8 + 2.5
20.9 + 2.1
25.2 ± 3.51)
22.6 + 5.0
24.3 ± 3.31)
27.1 ± 2.61)
28.4 ± 3.71)
4.2 ± 1.1
2.9 ± 0.82)
3.7 + 1.1
3.2 ± 0.82)
2.4 + 0.42)
2.8 ± 0.72)
8.4 ± 1.6
8.5 ± 1.4
10.9 + 4.3
9.2 + 1.8
9.9 + 0.91)
10.1 ± 1.51)
*) Values are mean ± S.D., with n = number of experiments (PC-32, total carbon atoms in acyl residues is 32).
J
·
2) Significantly higher (lower) (p < 0.01) compared with the control values.
methasone-L-carnitine groups (20 mg/kg and 40 mg/
kg) there is a further decrease, whereas after adminis-
tration of the betamethasone-L-carnitine (80 mg/kg)
combination, the same level äs in the betamethasone
group was found.
No increase was found in the proportion of 16: l/
16:0-PC following betamethasone treatment, äs
compared with the control group, whereas a marked
increase was found after L-carnitine administration.
The betamethasone-L-carnitine combination groups
showed significantly (p < 0.01) enhanced levels.
In quantitative terms (mg/g dry weight), the same
effects described above were found for both 16: O/
16 :1-PC and 16 :1/16 : 0-PC (data not shown).
phosphatidylcholiiie, which consists of dipalmitoyl-
phosphatidylcholine and PC-30. It was therefore of
interest to examine whether the different treatments
would affect dipalmitoylphosphatidylchöline exclüsi-
vely, or both disaturated species. As shown in table
2, betamethasone treatment resulted in an increase of
the PC-30 portion in the phosphatidylcholine species
compared with the controls, whereas no response
to L-carnitine was noted. It is of interest that the
betamethasone-L-carnitine (40 mg/kg) combination
resulted in a moderate enhancement, whereas in the
betamethasone-L-carnitine (20 mg/kg and 80 mg/kg)
combination groups no response was noted.
Composition of the phosphatidylcholine
species (tab. 2)
Palmitoyl-myristoyl phosphatidylcholine (PC-30):
most commonly used methods for surfactant determi-
nation are based on the determination of disaturated
Composition
fatty acids
of the phosphatidylcholine
Table 3 shows the relative composition of the esteri-
fied fatty acids in foetal hing phosphatidylcholine.
We have previously shown that each fatty acid is
present in more than one phosphatidylcholine species
Tab. 2. Relative phosphatidylcholine species composition in foetal rat lungs*).
Treatment PC-30 PC-32 PC-34 PC-36 PC-38
NaCl (Controls)
Betamethasone (0.3 mg/kg)
Carnitine (20 mg/kg)
Betamethasone + Carnitine (20 mg/kg)
Betamethasone + Carnitine (40 mg/kg)
Betamethasone + Carnitine (80 mg/kg)
16
14
6
12
10
12
7.1 + 2.5
8.9 + 2.0
7.2 + 1.6
6.9 + 2.6
7.9 + 1.8
7.1 ± 1.3
33.5 + 3.3
36.5 + 4.7
37.1 + 8.41)
36.9 + 4.21)
39.4 + 2.92)
40.6 ± 4.72)
33.7 + 2.8
29.3 + 2.3
30.8 + 2.93)
30.4 + 3.6
29.0 + 2.44)
28.0 + 3.34)
19.2 + 2.6
17.5 + 2.7
17.4 + 1.3
17.7 + 2.6
16.7 + 3.0
16.5 ± 2.7
6.3 + 1.5
8.0 -f 3.4
7.2 4- 4.8
8.9 1.7
6.9 + 1.9
7.6 2.3
*) Values are mean ± S. D., with n = number of experiments (PC-30 etc., total carbon atoms in acyl residues is 30 etc.).
) Significantly higher (p < 0.05) compared with the control values.
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Tab. 3. Relative composition of esterified phosphaditylcholine fatty acids in foetal rat lungs*).
Treatment 14:0 16:0 16:1 18:0 18:1 18:2 20:4
NaCl (Controls)
Betamethasone
(0.3 mg/kg)
Carnitine (20 mg/kg)
Betamethasone
+ Carnitine (20 mg/kg)
Betamethasone
+ Carnitine (40 mg/kg)
Betamethasone
4- Carnitine (80 mg/kg)
15 3.7 ± 0.8 39.2 ± 1.7
13 3.7 ± 0.7 40.8 ± 2.0
6 4.0 ± 0.8 41.3 ± 4.0
16 3.5 ± 0.5 42.2 ± 2.3
8 3.7 ± 0.6 41.6 ± 1.9
13 4.1 ± 1.0 41.5 ± 2.7
9.8 ± 1.0 10.6 ± 1.5 21.7 ± 1.5 4.8 ± 0.6 7.3 ± 1.4
9.5 ± 1.1 11.0 ± 1.7 18.5 ± 0.91) 6.0 ± 0.83) 7.6 ± 1.3
10.3 ± 1.2 9.7 ± 1.6 19.6 ± 1.52) 4.6 ± 0.6 7.3 ± 1.3
9.8 ± 0.9 8.5 ± 1.3 19.5 ± 3.32) 5.7 ± 0.5 7.2 ± 1.3
9.7 ± 0.7 9.5 ±1.4 18.0 ± l.O1) 5.4 ± 0.6 7.8 ± 0.7
9.3 ± 1.2 9.8 ±1.8 19.1 ± 2.31) 5.8 ± 0.73) 7.4 ± 1.9
*) Values are mean ± S. D., with n = number of experiments. 14: 0, myristic acid; 16:0, palmitic acid; 16:1, palmitoleic acid;
18 : 0, stearic acid; 18:1, oleic acid; 18:2, linoleic acid; 20 :4, arachidonic acid.
I l) Significantly lower (p < 0.01),| 2) significantly lower (p < 0.05),
I 1 . 3) significantly higher (p < 0.01) compared with the control group.
(7, 8). For instance, palmitic acid (16:0) occurs in
PC-30, in the two PC-32 monoenic species (16: O/
16 : l-PC and 16:1/16: 0-PC), in dipalmitoylphos-
phatidylcholine (16 : 0/16 : (WPC), and represents äs
16:0/18: l-PC the dominant fraction of PC-34 (8).
Thus, it is not surprising that the alterations in the
phosphatidylcholine fatty acid pattern are less pro-
nounced compared with the marked changes of the
phosphatidylcholine species composition (tab. 2). In
spite of the fact that many studies on the Stimulation
of surfactant synthesis are based on the portion of
palmitic acid in total fatty acids of hing phosphatidyl-
choline, it is of interest to note that in the present
study, no accordance between the proportion of pal-
mitic acid and the dipalmitoylphosphatidylcholine
Content was found (tab. l, 3).
Carnitine
Table 4 shows the content of total carnitine in the
foetal lungs. Betamethasone failed to ißfluence the
carnitine content. Materaal L-carnitine administra-
tion (20 mg/kg) resulted in a significant increase (p <
0.01). The same carnitine level was attained following
treatment with 20 mg/kg or with 40 mg/kg beta-
methasone-L-carnitine. Administration of a beta-
methasone-jL-carnitine (80 mg/kg) combination re-
sulted in a further, but not dose-related increase. The
Proportion of short-chain acyl-carnitine in the total
carnitine was relatively constant in all groups (data
not shown).
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Tab. 4. Total ,-carnitine content in foetal rat lungs*).
Treatment
NaCl (Controls)
Betamethasone (0.3 mg/kg)
Carnitine (20 mg/kg)
Betamethasone H- Carnitine (20 mg/kg)
Betamethasone H- Carnitine (40 mg/kg)
Betamethasone + Carnitine (80 mg/kg)
n
16
14
6
12
10
12
Total
L-carnitine
(nmol/g
frozen weight)
116 + 27
119 + 33
222 H- 471)
215 ± 241)
218 + 561)
262 + 9l1)
*) Values are mean ± S.D., with n = number of experiments.
l) Significantly higher (p < 0.01) compared to the control
group and the betamethasone-treated group.
Foetal weight and foetal lung weight (tab. 5)
As shown in numerous animal experiments maternal
treatment with corticosteroids resulted in a decrease
of foetal weight and in a marked reduction of the
foetal lung weight (13 —16). Also, in the present study
the lowest foetal body weights and foetal lung weights
were found in the betamethasone-treated group (tab.
5). Administration of L-carnitine resulted in an en-
hancement of both foetal weight and foetal lung
weight (p < 0.01) compared with the control group
and the other treatment groups. Interestingly, treat-
ment with the betamethasone-L-carnitine (80 mg/kg)
combination resulted in a reduction of the foetal
lung weight comparable to that of the betamethasone
group.
366 Lohninger et al.: Phosphatidylcholine species composition in foetal rat lungs
Tab. 5. Body weight and lung weight of the foetal rats*).
Treatment
NaCl (Controls)
Betamethasone (0.3 mg/kg)
Carnitine (20 mg/kg)
Betamethasone -f Carnitine (20 mg/kg)
Betamethasone + Carnitine (40 mg/kg)
Betamethasone + Carnitine (80 mg/kg)
n
17
14
6
14
10
15
Body weight
(g)
3.0 H- 0.6
2.6 + 0.5
3.3 + 0.82)
2.6 + 0.9
2.8 -f 0.4
2.8 + 0.7
Lung weight
(mg)
58.2 -f 12.9
< f
 48.6 + 11.2
78.0 + 26.71)
54.8 + 15.3
58.8 ± 13.8
50,8 + 13.8
*) Values are mean ± S.D., with n = number of experiments.
1) Significantly higher (p < 0.01) compared with all other experimental groups.
2) Significantly higher (p < 0.01) compared with the values of the betamethasone, and the betamethasone -f carnitine groups.
Discussion
Weinhold et al. (17) have shown that 50 to 60% of
foetal rats delivered two days prematurely survive
when placedan an incubator, while foetuses delivered
three days before term did not survive. In the present
study the foetal rats were delivered three days before
term, in contrast to previous studies in which delivery
was performed two days prematurely (4).
Betamethasone
It has been reported that relatively low doses of
betamethasone (0.25 mg/kg) given to the pregnant
rabbit increase the rate of choline incorporation into
phosphatidylcholine by foetal lung. However, larger
doses maternally administered cause foetal death,
apparently due to premature aging of the placenta
(18). In the present study no increase in total phos-
pholipid- and dipalmitoylphosphatidylcholine-con-
tents with respect to dry weight were found after
administration of 0.3 mg/kg betamethasone to the
mother animals. This is in accordance with studies
on rhesus monkeys (19, 20). Funkhäuser et al. (21)
showed that dexamethasone exposure does not in-
crease the total amount of surfactant per lung.
It is of interest to note that betamethasone treatment
also influences palmitoyl-myristoyl phosphatidylcho-
line (PC-30) both in quantitative and relative terms
(tab. 2). The role of PC-30 is unclear. Goerke et al.
(22) reported that PC-30 did not meet with all of the
criteria of surfactant material.
As reported previously (4) the two monoenic PC-32
species (16:0/16: l-PC and 16 :1/16 : 0-PC) are of
special interest, because the types of phosphatidyl-
choline that they contain are different in foetal lungs
and the lungs of adult animals (tab. 1).
These results were substantiated by the study of
Longmuir et al. (23). An unusually high portion of
palmitoleic acid (16:1), which was more than oüe-
fourth of the total fatty acids of the lamellar body
phosphatidylcholine frpm foetal rabbit lungs, was
found.
Carnitine
In contrast to glucocorticoids, no toxic side effects
are produced by L-carnitine (L-3-hydroxy-4-N-trime-
thylaminobutyrate) (24, 25). In addition to the well
established role of carnitine in the oxidation of fatty
acids in mitochondria, several additional fuiictions
of carnitine in cell metaßollsm have been reported
(summarized recently, (4)).
In the rat foetus plasma (26) and tissue (27, 28) levels
of both free and short-chain acyl-carnitine are low
and increa.se up to parturition. As in the foetal rat,
the rate of carnitine synthesis is low in the human
foetus (29). Furthermore, maternal plasma carnitine
concentrations are strongly reduced during preg-
nancy (29-31).
The rate of fatty acid oxidation is low during the
intrauterine phase (32). Shortly after parturition there
is a striking increase in energy production by fatty
acid oxidation due to the interrupted maternal glu-
cose supply. At this time tissue carnitine levels must
be sufficiently high for free fatty acid mobilization
from endogenous Stores (33, 34) äs well äs for fatty
acid oxidation in various tissues, accompanied in the
liver by ketone body production (35). It is of interest
to note that the rate of fatty acid synthesis from
acetoacetate is two or three times greater than from
glucose in developing rat lung .(36). Thereföre, im-
mediately after parturition, a^sufficient anioünt of
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ketone bodies is necessary for the synthesis of surfac-
tant precursors to meet the need for surfactant post-
natally.
Administration of L-carnitine to pregnant rats elev-
ated the carnitine in foetal lungs to a level approxi-
mately twice that of the controls (tab. 4) and roughly
equivalent to that of untreated animals at term.
Carnitine-betamethasone combination
The combined administration of betamethasone and
L-carnitine resulted in two different effects: additive
or subtractive effects, and effects apparently specific
for the combination.
Using a Standard betamethasone dose of 0.3 mg/kg
the best results were obtained in combination with
80 mg/kg L-carnitine. The enhancement of the dipal-
mitoylphosphatidylcholine content of foetal lungs is
obviously specific for the combination, since this
effect was not found after betamethasone or L-carni-
tine treatment alone (tab. 1). However, there was
rather an additive effect of the betamethasone-L-
carnitine combination on PC-30 and 16:1/16: 0-PC.
Little is known about interactions of carnitine and
glucocorticoids. In studies on carnitine transport
across the plasma membrane an increased uptake in
the presence of prednisolone was noted (37, 38). In
human systemic carnitine deficiency, corticosteroid
treatment is known to be beneficial (39). It is also
possible that the effect of the betamethasone-L-carni-
tine combination is mediated by other mechanisms.
Chaudhary et al. (40) found an increased cyclic AMP
(cAMP) level in foetal rat lungs after dexamethasone
treatment. An important role of cAMP in the regula-
tion of surfactant production by foetal lungs has
been postulated (41). Glucocorticoids promote the
conversion of foetal thyroxine (T4) to triiodothyro-
nine (T3) rather than reverse T3, and this could ac-
count for the increase in T3 levels (42). Accelerated
lung maturation after treatment either with T4 or T3
has been reported. Since T4 enhances the activity of
enzymes involved in carnitine metabolism it was also
of interest to investigate the effect of an L-carnitine-
thyroxine combination. The results of these experi-
ments will be published elsewhere.
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